Enclomiphene Citrate for Secondary Hypogonadism

What Is Enclomiphene Citrate and Why Is It Used Off-Label?

Enclomiphene citrate is the trans-isomer of clomiphene citrate, isolated to remove the cis-isomer (zuclomiphene) that accumulates in tissue and drives most estrogenic side effects. The FDA has never approved enclomiphene for the treatment of hypogonadism in men. Its off-label use in secondary hypogonadism is supported by Phase II and Phase III randomized controlled trial data, but prescribers carry the regulatory burden of using it outside any approved indication.

FDA-Approved Status vs. Off-Label Reality

The FDA approved clomiphene citrate (Clomid) decades ago for female ovulatory dysfunction, not for male hypogonadism [1]. Enclomiphene itself was studied under an Investigational New Drug application by Repros Therapeutics. The company filed for FDA approval of Androxal (enclomiphene 25 mg) for secondary hypogonadism but withdrew after the agency requested additional cardiovascular outcome data [2]. Prescribers writing enclomiphene today do so under the general off-label prescribing framework recognized by the FDA, which permits physicians to use approved drugs or compounded preparations for indications not on the label when clinical evidence supports the decision [3].

Why Secondary Hypogonadism Specifically?

Secondary hypogonadism is defined by low serum testosterone combined with low or inappropriately normal LH and FSH, indicating a failure at the hypothalamic or pituitary level rather than at the testes [4]. Because the testes retain functional capacity, an agent that restores upstream signaling can restart endogenous production. Enclomiphene blocks estrogen receptors at the hypothalamus, removing the negative-feedback brake on GnRH pulsatility, which raises LH and FSH and drives testicular testosterone synthesis [5]. This mechanism makes it biologically rational for secondary, but not primary, hypogonadism.

Mechanism of Action: How Enclomiphene Restores the HPG Axis

Enclomiphene acts as an estrogen receptor antagonist at the hypothalamus and pituitary. Estrogen normally suppresses GnRH release; blocking those receptors increases GnRH pulse frequency, which raises pituitary LH and FSH secretion [5]. LH then binds Leydig cells to stimulate testosterone synthesis, while FSH supports Sertoli cell function and spermatogenesis.

Comparison to Clomiphene Citrate

Racemic clomiphene contains roughly 38% enclomiphene and 62% zuclomiphene by commercial formulation. Zuclomiphene has a half-life measured in weeks and accumulates, producing prolonged estrogenic effects that may worsen mood, libido, and lipid profiles [6]. Enclomiphene's half-life is approximately 10 hours, which means it clears between doses and is less likely to produce cumulative estrogenic tissue effects [6]. A crossover pharmacokinetic study published in the Journal of Clinical Pharmacology found that enclomiphene produced equivalent LH stimulation with a substantially lower estradiol elevation compared to racemic clomiphene [6].

Why This Mechanism Preserves Fertility

Exogenous testosterone suppresses LH and FSH through negative feedback, reducing intratesticular testosterone to levels that halt sperm production. A single 200 mg testosterone enanthate injection can suppress sperm counts to azoospermic or severely oligospermic levels within 6 to 10 weeks in most men [7]. Enclomiphene does the opposite: it raises LH and FSH, preserving or increasing sperm output. This is the central clinical differentiator for men who want both symptom relief and future fertility.

Clinical Trial Evidence

Phase II Dose-Finding Data

A Phase II dose-ranging randomized controlled trial enrolled 163 men with secondary hypogonadism (morning testosterone <300 ng/dL, LH <12 IU/L) and randomized them to enclomiphene 12.5 mg, 25 mg, or placebo for 3 months [8]. At 12 weeks, 71% of men in the 12.5 mg arm and 86% in the 25 mg arm achieved testosterone >300 ng/dL, compared with 20% on placebo (P<0.001) [8]. Mean testosterone in the 25 mg group rose from 190 ng/dL at baseline to 418 ng/dL at week 12 [8]. LH and FSH both increased significantly, confirming the hypothalamic mechanism rather than a direct gonadal effect [8].

Phase III: Enclomiphene vs. Placebo and vs. Topical Testosterone

The key Phase III program for Androxal included two parallel trials, ZA-304 and ZA-305, conducted across multiple US sites in men with secondary hypogonadism [9]. In the active-controlled arm, 12 weeks of enclomiphene 25 mg was compared with AndroGel 1.62% (testosterone gel) and placebo. Enclomiphene produced testosterone normalization (>300 ng/dL) in approximately 90% of completers, non-inferior to AndroGel on that endpoint [9]. Sperm concentration in the enclomiphene arm increased by a median of 3.5 million/mL from baseline, while it fell by 12 million/mL in the AndroGel arm, a difference that was statistically significant (P<0.001) [9]. These data formed the core of Repros Therapeutics' NDA package submitted to the FDA in 2013 [2].

Extended Use: 6-Month and 12-Month Data

A subset of participants from the Phase III program continued open-label enclomiphene for up to 12 months [10]. Testosterone remained in the normal range (>300 ng/dL) in 84% of men at month 12, and sperm concentration was maintained above baseline in 78% of the cohort [10]. No new safety signals emerged beyond those seen in the 3-month controlled phase. The absence of a 24-month or longer placebo-controlled trial is the primary reason the FDA requested additional data before approval [2].

Real-World and Retrospective Data

A 2021 retrospective analysis of 85 men treated with compounded enclomiphene 12.5 to 25 mg at a men's health clinic reported that 79% achieved testosterone >350 ng/dL at 8 to 12 weeks, with a mean increase from 231 ng/dL to 489 ng/dL [11]. Symptom scores on the Androgen Deficiency in Aging Males (ADAM) questionnaire improved in 68% of responders [11]. Because this was a single-center retrospective study without a control arm, it is classified as GRADE C evidence, but the magnitude of response is consistent with the Phase III program [11].

GRADE Evidence Summary for Off-Label Use

Applying the GRADE framework to enclomiphene's evidence base for secondary hypogonadism yields a Moderate quality rating. The Phase II and Phase III RCTs are methodologically sound, with clear allocation concealment and pre-specified primary endpoints [8, 9]. Limitations that prevent a High rating include: the absence of an FDA-approved indication (the agency's cardiovascular concern has not been answered with a long-term outcomes trial), relatively small sample sizes by cardiovascular outcome trial standards, and a 12-month maximum follow-up in the best available dataset [10]. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism notes that SERMs including clomiphene represent an alternative to TRT in men with secondary hypogonadism who wish to maintain fertility, but stops short of recommending them as first-line because of limited long-term safety data [4]. The American Urological Association's 2018 guideline on testosterone deficiency similarly lists SERM therapy as an option for men desiring future fertility [12].

Dosing and Administration

Starting Dose

The most commonly used starting dose in clinical practice and in the Phase III trials is enclomiphene 12.5 mg orally once daily in the morning, titrated to 25 mg if testosterone response is insufficient after 6 to 8 weeks [8, 9]. Some practitioners use 25 mg from the outset in men with severe suppression (testosterone <150 ng/dL), though this increases the risk of estradiol elevation and is not supported by head-to-head dose comparison beyond the Phase II data [8].

Titration and Monitoring Schedule

Labs should be drawn fasting in the morning, ideally between 7 AM and 10 AM to capture peak diurnal testosterone. A reasonable monitoring schedule follows this pattern:

• Baseline: Total testosterone, free testosterone (calculated), LH, FSH, estradiol, CBC, lipid panel, PSA (men over 40)
• Week 6 to 8: Total testosterone, LH, FSH, estradiol. Adjust dose if testosterone <300 ng/dL or estradiol >42 pg/mL
• Week 12: Full repeat panel including CBC and lipids
• Every 6 months thereafter: Total testosterone, estradiol, CBC, lipid panel

When to Add an Aromatase Inhibitor

Enclomiphene raises testosterone, and a portion converts to estradiol via aromatase, particularly in men with higher adiposity [13]. If estradiol rises above 42 pg/mL (the upper limit of the male reference range at most labs) with symptomatic estrogen excess (gynecomastia, water retention, mood changes), low-dose anastrozole 0.25 to 0.5 mg twice weekly may be added [13]. This combination is itself off-label and lacks controlled trial data specific to enclomiphene, so it should be used cautiously with continued estradiol monitoring [13].

Safety Profile

Common Adverse Effects

In the Phase III program, adverse events were generally mild and not significantly different from placebo in incidence [9]. The most commonly reported events were headache (8% vs. 6% placebo), nausea (5% vs. 4%), and mood changes (6% vs. 5%) [9]. Visual symptoms, a recognized class effect of SERMs, occurred in approximately 2% of enclomiphene-treated men, consistent with rates reported with racemic clomiphene [9]. All visual events were transient and resolved after discontinuation [9].

Cardiovascular and Lipid Considerations

The FDA's primary concern before approving Androxal was the absence of long-term cardiovascular outcome data [2]. Enclomiphene's effect on lipids is mixed: HDL cholesterol may decrease modestly (mean change of approximately minus 4 mg/dL in the Phase III data), while LDL showed no significant change from baseline [9]. Men with existing dyslipidemia or elevated cardiovascular risk should have lipid panels checked at baseline and at 3 months [14]. The American Heart Association's 2020 position on testosterone therapy and cardiovascular risk does not specifically address enclomiphene but recommends caution with any agent that meaningfully alters sex hormone levels in men with established cardiovascular disease [14].

Erythrocytosis Risk

Exogenous testosterone is well-documented to raise hematocrit, sometimes to levels above 52 to 54% that require phlebotomy or dose reduction [4]. Enclomiphene raises endogenous testosterone through the HPG axis, and early data suggest erythrocytosis risk is substantially lower. In the 12-month open-label extension, hematocrit exceeded 52% in only 3.5% of men, compared with rates of 10 to 25% reported with intramuscular testosterone esters [10, 15]. This makes enclomiphene a reasonable option for men at higher baseline risk of erythrocytosis, such as those with obstructive sleep apnea or chronic mountain residence [15].

Contraindications

Enclomiphene should not be used in men with primary hypogonadism (Klinefelter syndrome, bilateral anorchia, severe testicular failure), because the testes cannot respond to LH stimulation regardless of upstream drive [4]. Men with active liver disease should avoid it, given clomiphene class hepatic metabolism concerns. A personal or family history of retinal disease warrants ophthalmology evaluation before starting, given the SERM class risk of visual disturbance [16].

Enclomiphene vs. Testosterone Replacement Therapy: A Direct Comparison

Testosterone Endpoints

Both enclomiphene 25 mg and AndroGel 1.62% normalized serum testosterone (>300 ng/dL) in approximately 90% of treated men at 12 weeks in the Phase III active-controlled trial [9]. The distributions differed: topical testosterone produced higher peak testosterone values (mean 567 ng/dL vs. 448 ng/dL with enclomiphene), but enclomiphene produced fewer values above 800 ng/dL, suggesting a more physiologic ceiling effect mediated by endogenous feedback [9].

Fertility and Spermatogenesis

This is the clearest clinical differentiator. TRT suppresses spermatogenesis reliably. Enclomiphene preserves and often improves it [9]. For men under 40 who have not completed their families, this distinction changes the treatment decision entirely. The Endocrine Society guideline states: "We suggest against using testosterone therapy in men who are currently desiring fertility" [4].

Symptom Improvement

The Phase III program used the ADAM questionnaire and the International Index of Erectile Function (IIEF) as secondary endpoints. Both enclomiphene and AndroGel improved ADAM scores significantly versus placebo [9]. IIEF scores improved comparably between the two active arms, suggesting comparable symptomatic benefit for most men with secondary hypogonadism [9]. Men with severe testosterone deficiency (baseline <150 ng/dL) showed numerically greater IIEF improvement with AndroGel, though the difference did not reach statistical significance in the subgroup analysis [9].

Logistics and Cost

Testosterone products require injection technique (for IM forms) or daily gel application with transfer precautions. Enclomiphene is a once-daily oral tablet, which some men find simpler to adhere to. Compounded enclomiphene from a 503A pharmacy currently costs approximately $40, $80 per month in the United States, competitive with brand-name testosterone gels but lower than many injectable testosterone formulations with all associated supplies [11].

Who Is a Candidate for Off-Label Enclomiphene?

The ideal candidate has:

1. Documented secondary hypogonadism (morning total testosterone <300 ng/dL on two separate draws, with low or inappropriately normal LH and FSH) [4]
2. Functional testes confirmed by LH/FSH pattern and ideally semen analysis
3. Desire to preserve fertility or active family planning
4. No history of primary testicular failure, active liver disease, or retinal pathology

Men with obesity-related hypogonadism (BMI >30, low LH, low testosterone) are particularly responsive because the underlying HPG suppression is often reversible and the aromatase excess from adipose tissue can be partially countered by increased LH-driven testosterone output [13]. A 2022 analysis of overweight men (mean BMI 33.4) with secondary hypogonadism showed that 12 weeks of enclomiphene 25 mg raised mean testosterone from 224 ng/dL to 461 ng/dL, with concurrent improvement in fasting insulin sensitivity, though this study was observational and not powered for metabolic endpoints [17].

Regulatory and Prescribing Considerations

Prescribers must document their clinical reasoning when using enclomiphene off-label. Best practices include:

• Confirming the diagnosis with two fasting morning testosterone measurements and an LH/FSH panel [4]
• Documenting that FDA-approved alternatives were considered and that the off-label choice serves the patient's specific clinical needs (fertility preservation being the most defensible rationale)
• Obtaining a compounded enclomiphene formulation from an FDA-registered 503A compounding pharmacy, since no commercially manufactured enclomiphene product holds current FDA approval for hypogonadism [3]
• Providing written informed consent that explicitly states the off-label status

The FDA's guidance on compounded drugs does not prohibit physicians from prescribing compounded enclomiphene for a patient with a documented medical need, but it does require that the compounding pharmacy meet applicable USP standards [3].